18:15 , Sep 7, 2018 |  BC Week In Review  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at more...
20:15 , Sep 6, 2018 |  BC Extra  |  Company News

Driver launches with cancer trial matching app

Driver Inc. debuted with a platform to match patients to clinical trials based on tumor and saliva samples and medical records. The company’s app presents customers with clinical trials for which they are eligible at more...
22:48 , Jan 5, 2018 |  BC Week In Review  |  Company News

Adaptive, Microsoft to develop universal TCR-antigen map

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Microsoft Corp.(NASDAQ:MSFT) partnered to develop a universal map of T cell receptors (TCRs) and their antigens using Adaptive's immunosequencing platform and Microsoft's research, machine-learning and cloud computing technologies. The...
00:20 , Jan 5, 2018 |  BC Extra  |  Company News

Adaptive, Microsoft to develop universal TCR-antigen map

Adaptive Biotechnologies Corp. (Seattle, Wash.) and Microsoft Corp.(NASDAQ:MSFT) partnered to develop a universal map of T cell receptors (TCRs) and their antigens using Adaptive's immunosequencing platform and Microsoft's research, machine-learning and cloud computing technologies. The...
23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the Adaptive...
19:56 , May 24, 2017 |  BC Innovations  |  Translation in Brief

Unusual suspects

While viral proteins have been considered prime targets for immunotherapy in cancers triggered by viral infections, an NCI study indicates mutated host antigens could be equally or more immunogenic. The study, published in Science last month,...
16:07 , Mar 28, 2017 |  BC Innovations  |  Translation in Brief

Minority power

A Science Immunology study suggests the most potent antitumor T cells in patients may originate from the least abundant T cell clones in their blood. The authors are now investigating the gene expression signatures of...
00:38 , Mar 23, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens; drug platforms

TECHNOLOGY: Cellular assays; peptides A genomic and proteomic screening method could identify neoantigens as personalized immunotherapy targets for cancer. The method involved collecting tumor and non-tumor tissue samples from a patient; immunoprecipitating human leukocyte antigen class...
00:02 , Mar 2, 2017 |  BC Extra  |  Financial News

Grail raises $900M toward planned $1B round

Cancer screening company Grail Inc. (Menlo Park, Calif.) said it raised more than $900 million in the first close of a series B financing. The company expects a second close this quarter that would raise...
22:27 , Jan 6, 2017 |  BioCentury  |  Finance

Billion dollar baby

With what could be more than a $1 billion B round in the works, cancer screening company Grail Inc. is on track to set a new private financing record. The round is expected to close...